LivsMed
PublicLivsMed is now publicly traded
The data on this page reflects LivsMed's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Dec 24, 2025
Last Round
Private Equity
Feb 25, 2025
Est. Valuation at Exit
$642.32M
Total Funding Raised
$155.14M
Company Overview
The recorded funding history for LivsMed includes a Private Equity round in February 2025. LivsMed has raised $155.14M.
LivsMed is a medical devices company that develops articulating instruments designed for precision in minimally invasive surgery.
AI Layer
Application
LivsMed Comparables
Compare LivsMed with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| FlexDex Surgical | 85% | |
| Applied Medical | 75% | |
| Distalmotion | 74% |
For institutional investors. Book with your work email.
LivsMed Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Dec 24, 2025 | ||||
| Private Equity | Feb 25, 2025 | ||||
| Series E Extension | Oct 19, 2023 | ||||
| Series D | Sep 13, 2020 | ||||
| Series A | Jul 1, 2016 | ||||
Series A | Mar 1, 2015 |
For institutional investors. Book with your work email.
LivsMed Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| K2 Investment Partners | Series D |
| Samsung Securities Co., Ltd. | IPO |
| Mirae Asset Securities | IPO |
| NH Investment & Securities | Private Equity |
| Timefolio Asset Management | Private Equity, Series E Extension, Series E |
| Wonik Investment Partners | Series D |
| Stonebridge Ventures | Series D, Series E Extension, Series C, Series A |
For institutional investors. Book with your work email.
LivsMed Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.